Amy R. Caivano

Amy grew up in Spring, TX and received a B.S. in Biology from Baylor University in Waco, TX. Since graduation she has worked in research labs at UT and Baylor and Encysive Pharmaceuticals. In 2008, after Pfizer purchased Encysive, Dr. James T. Willerson recruited her research group to join the department of Molecular Cardiology at THI where she remains today.

Show full bio

Amy enjoys traveling to National Parks with her husband where they love to camp and hike. Baking delicious treats is a favorite pastime of her too.

Hide full bio

See Publications

Texas Heart Institute Positions

Senior Research Associate, Molecular Cardiology Research

Interests

Non-invasive diagnostic imaging technologies

Education

Undergraduate:

Baylor University

Publications

4862227 4R4R39JD 1 alternatives-to-animal-experimentation 10 date desc Caivano 1850 https://www.texasheart.org/wp-content/plugins/zotpress/

%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22I7XSBSGG%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hickman%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHickman%2C%20A.%2C%20Koetsier%2C%20J.%2C%20Kurtanich%2C%20T.%20et%20al.%20%282022%29.%20LFA-1%20activation%20enriches%20tumor-specific%20T%20cells%20in%20a%20cold%20tumor%20model%20and%20synergizes%20with%20CTLA-4%20blockade.%20%26lt%3Bi%26gt%3BJ%20Clin%20Invest%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B132%26lt%3B%5C%2Fi%26gt%3B%2C%20e154152.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI154152%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI154152%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LFA-1%20activation%20enriches%20tumor-specific%20T%20cells%20in%20a%20cold%20tumor%20model%20and%20synergizes%20with%20CTLA-4%20blockade%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amber%22%2C%22lastName%22%3A%22Hickman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joost%22%2C%22lastName%22%3A%22Koetsier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trevin%22%2C%22lastName%22%3A%22Kurtanich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20C.%22%2C%22lastName%22%3A%22Nielsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glenn%22%2C%22lastName%22%3A%22Winn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yunfei%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salah-Eddine%22%2C%22lastName%22%3A%22Bentebibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leilei%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Punt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cara%22%2C%22lastName%22%3A%22Haymaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20B.%22%2C%22lastName%22%3A%22Chesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Fa%27ak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20L.%22%2C%22lastName%22%3A%22Dominguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isere%22%2C%22lastName%22%3A%22Kuiatse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Navin%20D.%22%2C%22lastName%22%3A%22Warier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Upendra%22%2C%22lastName%22%3A%22Marathi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Craft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Hwu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adi%22%2C%22lastName%22%3A%22Diab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Willem%20W.%22%2C%22lastName%22%3A%22Overwijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yared%22%2C%22lastName%22%3A%22Hailemichael%22%7D%5D%2C%22abstractNote%22%3A%22The%20inability%20of%20CD8%2B%20effector%20T%20cells%20%28Teffs%29%20to%20reach%20tumor%20cells%20is%20an%20important%20aspect%20of%20tumor%20resistance%20to%20cancer%20immunotherapy.%20The%20recruitment%20of%20these%20cells%20to%20the%20tumor%20microenvironment%20%28TME%29%20is%20regulated%20by%20integrins%2C%20a%20family%20of%20adhesion%20molecules%20that%20are%20expressed%20on%20T%20cells.%20Here%2C%20we%20show%20that%207HP349%2C%20a%20small-molecule%20activator%20of%20lymphocyte%20function-associated%20antigen-1%20%28LFA-1%29%20and%20very%20late%20activation%20antigen-4%20%28VLA-4%29%20integrin%20cell-adhesion%20receptors%2C%20facilitated%20the%20preferential%20localization%20of%20tumor-specific%20T%20cells%20to%20the%20tumor%20and%20improved%20antitumor%20response.%207HP349%20monotherapy%20had%20modest%20effects%20on%20anti-programmed%20death%201-resistant%20%28anti-PD-1-resistant%29%20tumors%2C%20whereas%20combinatorial%20treatment%20with%20anti-cytotoxic%20T%20lymphocyte-associated%20protein%204%20%28anti-CTLA-4%29%20increased%20CD8%2B%20Teff%20intratumoral%20sequestration%20and%20synergized%20in%20cooperation%20with%20neutrophils%20in%20inducing%20cancer%20regression.%207HP349%20intratumoral%20CD8%2B%20Teff%20enrichment%20activity%20depended%20on%20CXCL12.%20We%20analyzed%20gene%20expression%20profiles%20using%20RNA%20from%20baseline%20and%20on%20treatment%20tumor%20samples%20of%2014%20melanoma%20patients.%20We%20identified%20baseline%20CXCL12%20gene%20expression%20as%20possibly%20improving%20the%20likelihood%20or%20response%20to%20anti-CTLA-4%20therapies.%20Our%20results%20provide%20a%20proof-of-principle%20demonstration%20that%20LFA-1%20activation%20could%20convert%20a%20T%20cell-exclusionary%20TME%20to%20a%20T%20cell-enriched%20TME%20through%20mechanisms%20involving%20cooperation%20with%20innate%20immune%20cells.%22%2C%22date%22%3A%22July%2001%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1172%5C%2FJCI154152%22%2C%22ISSN%22%3A%221558-8238%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226MADD4J5%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%224R4R39JD%22%2C%227STYFUFZ%22%2C%225QIRWFUY%22%2C%22TC3LQMP8%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A41%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22HH4AD2YI%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bakthavatsalam%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBakthavatsalam%2C%20D.%2C%20Craft%2C%20J.%20W.%2C%20Kazansky%2C%20A.%20et%20al.%20%282020%29.%20Identification%20of%20Inhibitors%20of%20Integrin%20Cytoplasmic%20Domain%20Interactions%20With%20Syk.%20%26lt%3Bi%26gt%3BFront%20Immunol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B11%26lt%3B%5C%2Fi%26gt%3B%2C%20575085.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.575085%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.575085%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Identification%20of%20Inhibitors%20of%20Integrin%20Cytoplasmic%20Domain%20Interactions%20With%20Syk%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deenadayalan%22%2C%22lastName%22%3A%22Bakthavatsalam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Craft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Kazansky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nghi%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Goeun%22%2C%22lastName%22%3A%22Bae%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Gundlach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asra%22%2C%22lastName%22%3A%22Aslam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Safa%22%2C%22lastName%22%3A%22Ali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shashikant%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%20Y.%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hema%20D.%22%2C%22lastName%22%3A%22Parthiban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clifford%20C.%22%2C%22lastName%22%3A%22Stephan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%5D%2C%22abstractNote%22%3A%22Leukocyte%20inflammatory%20responses%20require%20integrin%20cell-adhesion%20molecule%20signaling%20through%20spleen%20tyrosine%20kinase%20%28Syk%29%2C%20a%20non-receptor%20kinase%20that%20binds%20directly%20to%20integrin%20%5Cu03b2-chain%20cytoplasmic%20domains.%20Here%2C%20we%20developed%20a%20high-throughput%20screen%20to%20identify%20small%20molecule%20inhibitors%20of%20the%20Syk-integrin%20cytoplasmic%20domain%20interactions.%20Screening%20small%20molecule%20compound%20libraries%20identified%20the%20%5Cu03b2-lactam%20antibiotics%20cefsulodin%20and%20ceftazidime%2C%20which%20inhibited%20integrin%20%5Cu03b2-subunit%20cytoplasmic%20domain%20binding%20to%20the%20tandem%20SH2%20domains%20of%20Syk%20%28IC50%20range%2C%201.02-4.9%20%5Cu00b5M%29.%20Modeling%20suggested%20antagonist%20binding%20to%20Syk%20outside%20the%20pITAM%20binding%20site.%20Ceftazidime%20inhibited%20integrin%20signaling%20via%20Syk%2C%20including%20inhibition%20of%20adhesion-dependent%20upregulation%20of%20interleukin-1%5Cu03b2%20and%20monocyte%20chemoattractant%20protein-1%2C%20but%20did%20not%20inhibit%20ITAM-dependent%20phosphorylation%20of%20Syk%20mediated%20by%20Fc%5Cu03b3RI%20signaling.%20Our%20results%20demonstrate%20a%20novel%20means%20to%20target%20Syk%20independent%20of%20its%20kinase%20and%20pITAM%20binding%20sites%20such%20that%20integrin%20signaling%20via%20this%20kinase%20is%20abrogated%20but%20ITAM-dependent%20signaling%20remains%20intact.%20As%20integrin%20signaling%20through%20Syk%20is%20essential%20for%20leukocyte%20activation%2C%20this%20may%20represent%20a%20novel%20approach%20to%20target%20inflammation.%22%2C%22date%22%3A%222020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2020.575085%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%22VXDM6BAE%22%2C%224R4R39JD%22%2C%22XCUHKMZU%22%5D%2C%22dateModified%22%3A%222021-02-11T18%3A41%3A01Z%22%7D%7D%2C%7B%22key%22%3A%229LRIQ9XJ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Woodside%20et%20al.%22%2C%22parsedDate%22%3A%222018-02-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWoodside%2C%20D.%20G.%2C%20Tanifum%2C%20E.%20A.%2C%20Ghaghada%2C%20K.%20B.%20et%20al.%20%282018%29.%20Magnetic%20resonance%20imaging%20of%20atherosclerotic%20plaque%20at%20clinically%20relevant%20field%20strengths%20%281T%29%20by%20targeting%20the%20integrin%20%26%23x3B1%3B4%26%23x3B2%3B1.%20%26lt%3Bi%26gt%3BSci%20Rep%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B8%26lt%3B%5C%2Fi%26gt%3B%2C%203733.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-018-21893-x%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-018-21893-x%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Magnetic%20resonance%20imaging%20of%20atherosclerotic%20plaque%20at%20clinically%20relevant%20field%20strengths%20%281T%29%20by%20targeting%20the%20integrin%20%5Cu03b14%5Cu03b21%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20A.%22%2C%22lastName%22%3A%22Tanifum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ketan%20B.%22%2C%22lastName%22%3A%22Ghaghada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zbigniew%20A.%22%2C%22lastName%22%3A%22Starosolski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saakshi%22%2C%22lastName%22%3A%22Bhayana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahrzad%22%2C%22lastName%22%3A%22Abbasi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22Craft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20S.%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chandreshkumar%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%20V.%22%2C%22lastName%22%3A%22Stupin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deenadayalan%22%2C%22lastName%22%3A%22Bakthavatsalam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20V.%22%2C%22lastName%22%3A%22Market%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ananth%20V.%22%2C%22lastName%22%3A%22Annapragada%22%7D%5D%2C%22abstractNote%22%3A%22Inflammation%20drives%20the%20degradation%20of%20atherosclerotic%20plaque%2C%20yet%20there%20are%20no%20non-invasive%20techniques%20available%20for%20imaging%20overall%20inflammation%20in%20atherosclerotic%20plaques%2C%20especially%20in%20the%20coronary%20arteries.%20To%20address%20this%2C%20we%20have%20developed%20a%20clinically%20relevant%20system%20to%20image%20overall%20inflammatory%20cell%20burden%20in%20plaque.%20Here%2C%20we%20describe%20a%20targeted%20contrast%20agent%20%28THI0567-targeted%20liposomal-Gd%29%20that%20is%20suitable%20for%20magnetic%20resonance%20%28MR%29%20imaging%20and%20binds%20with%20high%20affinity%20and%20selectivity%20to%20the%20integrin%20%5Cu03b14%5Cu03b21%28very%20late%20antigen-4%2C%20VLA-4%29%2C%20a%20key%20integrin%20involved%20in%20recruiting%20inflammatory%20cells%20to%20atherosclerotic%20plaques.%20This%20liposomal%20contrast%20agent%20has%20a%20high%20T1%20relaxivity%20%28~2%5Cu2009%5Cu00d7%5Cu2009105%5Cu2009mM-1s-1%20on%20a%20particle%20basis%29%20resulting%20in%20the%20ability%20to%20image%20liposomes%20at%20a%20clinically%20relevant%20MR%20field%20strength.%20We%20were%20able%20to%20visualize%20atherosclerotic%20plaques%20in%20various%20regions%20of%20the%20aorta%20in%20atherosclerosis-prone%20ApoE-%5C%2F-%20mice%20on%20a%201%20Tesla%20small%20animal%20MRI%20scanner.%20These%20enhanced%20signals%20corresponded%20to%20the%20accumulation%20of%20monocyte%5C%2Fmacrophages%20in%20the%20subendothelial%20layer%20of%20atherosclerotic%20plaques%20in%20vivo%2C%20whereas%20non-targeted%20liposomal%20nanoparticles%20did%20not%20demonstrate%20comparable%20signal%20enhancement.%20An%20inflammatory%20cell-targeted%20method%20that%20has%20the%20specificity%20and%20sensitivity%20to%20measure%20the%20inflammatory%20burden%20of%20a%20plaque%20could%20be%20used%20to%20noninvasively%20identify%20patients%20at%20risk%20of%20an%20acute%20ischemic%20event.%22%2C%22date%22%3A%22Feb%2027%2C%202018%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-018-21893-x%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%226MADD4J5%22%2C%22WGZKEVDQ%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%22JH9V95Q8%22%2C%22VXDM6BAE%22%2C%224R4R39JD%22%2C%227STYFUFZ%22%2C%225QIRWFUY%22%5D%2C%22dateModified%22%3A%222018-05-07T19%3A32%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22NFZGT9TW%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vanderslice%20et%20al.%22%2C%22parsedDate%22%3A%222013-07-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVanderslice%2C%20P.%2C%20Biediger%2C%20R.%20J.%2C%20Woodside%2C%20D.%20G.%20et%20al.%20%282013%29.%20Small%20molecule%20agonist%20of%20very%20late%20antigen-4%20%28VLA-4%29%20integrin%20induces%20progenitor%20cell%20adhesion.%20%26lt%3Bi%26gt%3BJ%20Biol%20Chem%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B288%26lt%3B%5C%2Fi%26gt%3B%2C%2019414%26%23x2013%3B19428.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1074%5C%2Fjbc.M113.479634%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1074%5C%2Fjbc.M113.479634%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Small%20molecule%20agonist%20of%20very%20late%20antigen-4%20%28VLA-4%29%20integrin%20induces%20progenitor%20cell%20adhesion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20J.%22%2C%22lastName%22%3A%22Biediger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wells%20S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayadeth%22%2C%22lastName%22%3A%22Khounlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Navin%20D.%22%2C%22lastName%22%3A%22Warier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Gundlach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20G.%22%2C%22lastName%22%3A%22Bornmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20S.%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20W.%22%2C%22lastName%22%3A%22McIntyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%5D%2C%22abstractNote%22%3A%22Activation%20of%20the%20integrin%20family%20of%20cell%20adhesion%20receptors%20on%20progenitor%20cells%20may%20be%20a%20viable%20approach%20to%20enhance%20the%20effects%20of%20stem%20cell-based%20therapies%20by%20improving%20cell%20retention%20and%20engraftment.%20Here%2C%20we%20describe%20the%20synthesis%20and%20characterization%20of%20the%20first%20small%20molecule%20agonist%20identified%20for%20the%20integrin%20%5Cu03b14%5Cu03b21%20%28also%20known%20as%20very%20late%20antigen-4%20or%20VLA-4%29.%20The%20agonist%2C%20THI0019%2C%20was%20generated%20via%20two%20structural%20modifications%20to%20a%20previously%20identified%20%5Cu03b14%5Cu03b21%20antagonist.%20THI0019%20greatly%20enhanced%20the%20adhesion%20of%20cultured%20cell%20lines%20and%20primary%20progenitor%20cells%20to%20%5Cu03b14%5Cu03b21%20ligands%20VCAM-1%20and%20CS1%20under%20both%20static%20and%20flow%20conditions.%20Furthermore%2C%20THI0019%20facilitated%20the%20rolling%20and%20spreading%20of%20cells%20on%20VCAM-1%20and%20the%20migration%20of%20cells%20toward%20SDF-1%5Cu03b1.%20Molecular%20modeling%20predicted%20that%20the%20compound%20binds%20at%20the%20%5Cu03b1%5C%2F%5Cu03b2%20subunit%20interface%20overlapping%20the%20ligand-binding%20site%20thus%20indicating%20that%20the%20compound%20must%20be%20displaced%20upon%20ligand%20binding.%20In%20support%20of%20this%20model%2C%20an%20analog%20of%20THI0019%20modified%20to%20contain%20a%20photoreactive%20group%20was%20used%20to%20demonstrate%20that%20when%20cross-linked%20to%20the%20integrin%2C%20the%20compound%20behaves%20as%20an%20antagonist%20instead%20of%20an%20agonist.%20In%20addition%2C%20THI0019%20showed%20cross-reactivity%20with%20the%20related%20integrin%20%5Cu03b14%5Cu03b27%20as%20well%20as%20%5Cu03b15%5Cu03b21%20and%20%5Cu03b1L%5Cu03b22.%20When%20cross-linked%20to%20%5Cu03b1L%5Cu03b22%2C%20the%20photoreactive%20analog%20of%20THI0019%20remained%20an%20agonist%2C%20consistent%20with%20it%20binding%20at%20the%20%5Cu03b1%5C%2F%5Cu03b2%20subunit%20interface%20and%20not%20at%20the%20ligand-binding%20site%20in%20the%20inserted%20%28%26quot%3BI%26quot%3B%29%20domain%20of%20the%20%5Cu03b1L%20subunit.%20Co-administering%20progenitor%20cells%20with%20a%20compound%20such%20as%20THI0019%20may%20provide%20a%20mechanism%20for%20enhancing%20stem%20cell%20therapy.%22%2C%22date%22%3A%22Jul%2005%2C%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1074%5C%2Fjbc.M113.479634%22%2C%22ISSN%22%3A%221083-351X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%226MADD4J5%22%2C%22WGZKEVDQ%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%224R4R39JD%22%2C%227STYFUFZ%22%2C%22TC3LQMP8%22%5D%2C%22dateModified%22%3A%222018-05-02T21%3A14%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22XL74TS7P%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Haidari%20et%20al.%22%2C%22parsedDate%22%3A%222012-09-21%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHaidari%2C%20M.%2C%20Zhang%2C%20W.%2C%20%26lt%3Bstrong%26gt%3BCaivano%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20et%20al.%20%282012%29.%20Integrin%20%26%23x3B1%3B2%26%23x3B2%3B1%20mediates%20tyrosine%20phosphorylation%20of%20vascular%20endothelial%20cadherin%20induced%20by%20invasive%20breast%20cancer%20cells.%20%26lt%3Bi%26gt%3BJ%20Biol%20Chem%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B287%26lt%3B%5C%2Fi%26gt%3B%2C%2032981%26%23x2013%3B32992.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1074%5C%2Fjbc.M112.395905%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1074%5C%2Fjbc.M112.395905%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Integrin%20%5Cu03b12%5Cu03b21%20mediates%20tyrosine%20phosphorylation%20of%20vascular%20endothelial%20cadherin%20induced%20by%20invasive%20breast%20cancer%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehran%22%2C%22lastName%22%3A%22Haidari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wei%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhenping%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Ganjehei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmadreza%22%2C%22lastName%22%3A%22Mortazavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Stroud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%5D%2C%22abstractNote%22%3A%22The%20molecular%20mechanisms%20that%20regulate%20the%20endothelial%20response%20during%20transendothelial%20migration%20%28TEM%29%20of%20invasive%20cancer%20cells%20remain%20elusive.%20Tyrosine%20phosphorylation%20of%20vascular%20endothelial%20cadherin%20%28VE-cad%29%20has%20been%20implicated%20in%20the%20disruption%20of%20endothelial%20cell%20adherens%20junctions%20and%20in%20the%20diapedesis%20of%20metastatic%20cancer%20cells.%20We%20sought%20to%20determine%20the%20signaling%20mechanisms%20underlying%20the%20disruption%20of%20endothelial%20adherens%20junctions%20after%20the%20attachment%20of%20invasive%20breast%20cancer%20cells.%20Attachment%20of%20invasive%20breast%20cancer%20cells%20%28MDA-MB-231%29%20to%20human%20umbilical%20vein%20endothelial%20cells%20induced%20tyrosine%20phosphorylation%20of%20VE-cad%2C%20dissociation%20of%20%5Cu03b2-catenin%20from%20VE-cad%2C%20and%20retraction%20of%20endothelial%20cells.%20Breast%20cancer%20cell-induced%20tyrosine%20phosphorylation%20of%20VE-cad%20was%20mediated%20by%20activation%20of%20the%20H-Ras%5C%2FRaf%5C%2FMEK%5C%2FERK%20signaling%20cascade%20and%20depended%20on%20the%20phosphorylation%20of%20endothelial%20myosin%20light%20chain%20%28MLC%29.%20The%20inhibition%20of%20H-Ras%20or%20MLC%20in%20endothelial%20cells%20inhibited%20TEM%20of%20MDA-MB-231%20cells.%20VE-cad%20tyrosine%20phosphorylation%20in%20endothelial%20cells%20induced%20by%20the%20attachment%20of%20MDA-MB-231%20cells%20was%20mediated%20by%20MDA-MB-231%20%5Cu03b1%282%29%5Cu03b2%281%29%20integrin.%20Compared%20with%20highly%20invasive%20MDA-MB-231%20breast%20cancer%20cells%2C%20weakly%20invasive%20MCF-7%20breast%20cancer%20cells%20expressed%20lower%20levels%20of%20%5Cu03b1%282%29%5Cu03b2%281%29%20integrin.%20TEM%20of%20MCF-7%20as%20well%20as%20induction%20of%20VE-cad%20tyrosine%20phosphorylation%20and%20dissociation%20of%20%5Cu03b2-catenin%20from%20the%20VE-cad%20complex%20by%20MCF-7%20cells%20were%20lower%20than%20in%20MDA-MB-231%20cells.%20These%20processes%20were%20restored%20when%20MCF-7%20cells%20were%20treated%20with%20%5Cu03b2%281%29-activating%20antibody.%20Moreover%2C%20the%20response%20of%20endothelial%20cells%20to%20the%20attachment%20of%20prostatic%20%28PC-3%29%20and%20ovarian%20%28SKOV3%29%20invasive%20cancer%20cells%20resembled%20the%20response%20to%20MDA-MB-231%20cells.%20Our%20study%20showed%20that%20the%20MDA-MB-231%20cell-induced%20disruption%20of%20endothelial%20adherens%20junction%20integrity%20is%20triggered%20by%20MDA-MB-231%20cell%20%5Cu03b1%282%29%5Cu03b2%281%29%20integrin%20and%20is%20mediated%20by%20H-Ras%5C%2FMLC-induced%20tyrosine%20phosphorylation%20of%20VE-cad.%22%2C%22date%22%3A%22Sep%2021%2C%202012%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1074%5C%2Fjbc.M112.395905%22%2C%22ISSN%22%3A%221083-351X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%22WGZKEVDQ%22%2C%22Z2XX7DHR%22%2C%227XFQVVGN%22%2C%224R4R39JD%22%5D%2C%22dateModified%22%3A%222018-05-02T20%3A45%3A54Z%22%7D%7D%2C%7B%22key%22%3A%2228KA9LPJ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gundlach%20et%20al.%22%2C%22parsedDate%22%3A%222011-08-17%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGundlach%2C%20C.%20W.%2C%20%26lt%3Bstrong%26gt%3BCaivano%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%2C%20Cabreira-Hansen%2C%20M.%20da%20G.%20et%20al.%20%282011%29.%20Synthesis%20and%20evaluation%20of%20an%20anti-MLC1%20%26%23xD7%3B%20anti-CD90%20bispecific%20antibody%20for%20targeting%20and%20retaining%20bone-marrow-derived%20multipotent%20stromal%20cells%20in%20infarcted%20myocardium.%20%26lt%3Bi%26gt%3BBioconjug%20Chem%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B22%26lt%3B%5C%2Fi%26gt%3B%2C%201706%26%23x2013%3B1714.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Fbc200309h%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Fbc200309h%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Synthesis%20and%20evaluation%20of%20an%20anti-MLC1%20%5Cu00d7%20anti-CD90%20bispecific%20antibody%20for%20targeting%20and%20retaining%20bone-marrow-derived%20multipotent%20stromal%20cells%20in%20infarcted%20myocardium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Gundlach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20da%20Graca%22%2C%22lastName%22%3A%22Cabreira-Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amir%22%2C%22lastName%22%3A%22Gahremanpour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wells%20S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Zheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20W.%22%2C%22lastName%22%3A%22McIntyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20T.%22%2C%22lastName%22%3A%22Willerson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emerson%20C.%22%2C%22lastName%22%3A%22Perin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%5D%2C%22abstractNote%22%3A%22A%20key%20issue%20regarding%20the%20use%20of%20stem%20cells%20in%20cardiovascular%20regenerative%20medicine%20is%20their%20retention%20in%20target%20tissues.%20Here%2C%20we%20have%20generated%20and%20assessed%20a%20bispecific%20antibody%20heterodimer%20designed%20to%20improve%20the%20retention%20of%20bone-marrow-derived%20multipotent%20stromal%20cells%20%28BMMSC%29%20in%20cardiac%20tissue%20damaged%20by%20myocardial%20infarction.%20The%20heterodimer%20comprises%20an%20anti-human%20CD90%20monoclonal%20antibody%20%28mAb%29%20%28clone%205E10%29%20and%20an%20anti-myosin%20light%20chain%201%20%28MLC1%29%20mAb%20%28clone%20MLM508%29%20covalently%20cross-linked%20by%20a%20bis-arylhydrazone.%20We%20modified%20the%20anti-CD90%20antibody%20with%20a%20pegylated-4-formylbenzamide%20moiety%20to%20a%20molar%20substitution%20ratio%20%28MSR%29%20of%202.6%20and%20the%20anti-MLC1%20antibody%20with%20a%206-hydrazinonicotinamide%20moiety%20to%20a%20MSR%20of%200.9.%20The%20covalent%20modifications%20had%20no%20significant%20deleterious%20effect%20on%20mAb%20epitope%20binding.%20Furthermore%2C%20the%20binding%20of%20anti-CD90%20antibody%20to%20BMMSCs%20did%20not%20prevent%20their%20differentiation%20into%20adipo-%2C%20chondro-%2C%20or%20osteogenic%20lineages.%20Modified%20antibodies%20were%20combined%20under%20mild%20conditions%20%28room%20temperature%2C%20pH%206%2C%201%20h%29%20in%20the%20presence%20of%20a%20catalyst%20%28aniline%29%20to%20allow%20for%20rapid%20generation%20of%20the%20covalent%20bis-arylhydrazone%2C%20which%20was%20monitored%20at%20A%28354%29.%20We%20evaluated%20epitope%20immunoreactivity%20for%20each%20mAb%20in%20the%20construct.%20Flow%20cytometry%20demonstrated%20binding%20of%20the%20bispecific%20construct%20to%20BMMSCs%20that%20was%20competed%20by%20free%20anti-CD90%20mAb%2C%20verifying%20that%20modification%20and%20cross-linking%20were%20not%20detrimental%20to%20the%20anti-CD90%20complementarity-determining%20region.%20Similarly%2C%20ELISA-based%20assays%20demonstrated%20bispecific%20antibody%20binding%20to%20plastic-immobilized%20recombinant%20MLC1.%20Excess%20anti-MLC1%20mAb%20competed%20for%20bispecific%20antibody%20binding.%20Finally%2C%20the%20anti-CD90%20%5Cu00d7%20anti-MLC1%20bispecific%20antibody%20construct%20induced%20BMMSC%20adhesion%20to%20plastic-immobilized%20MLC1%20that%20was%20resistant%20to%20shear%20stress%2C%20as%20measured%20in%20parallel-plate%20flow%20chamber%20assays.%20We%20used%20mAbs%20that%20bind%20both%20human%20antigens%20and%20the%20respective%20pig%20homologues.%20Thus%2C%20the%20anti-CD90%20%5Cu00d7%20anti-MLC1%20bispecific%20antibody%20may%20be%20used%20in%20large%20animal%20studies%20of%20acute%20myocardial%20infarction%20and%20may%20provide%20a%20starting%20point%20for%20clinical%20studies.%22%2C%22date%22%3A%22Aug%2017%2C%202011%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1021%5C%2Fbc200309h%22%2C%22ISSN%22%3A%221520-4812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NNUFWYNJ%22%2C%22WGZKEVDQ%22%2C%228HHBIBI6%22%2C%227XFQVVGN%22%2C%22JK8LVZ9C%22%2C%224R4R39JD%22%2C%228PULYTSK%22%5D%2C%22dateModified%22%3A%222018-05-02T21%3A16%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22PUWTEI23%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vanderslice%20et%20al.%22%2C%22parsedDate%22%3A%222010-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVanderslice%2C%20P.%2C%20Woodside%2C%20D.%20G.%2C%20%26lt%3Bstrong%26gt%3BCaivano%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20R.%20et%20al.%20%282010%29.%20Potent%20in%20vivo%20suppression%20of%20inflammation%20by%20selectively%20targeting%20the%20high%20affinity%20conformation%20of%20integrin%20%26%23x3B1%3B4%26%23x3B2%3B1.%20%26lt%3Bi%26gt%3BBiochem%20Biophys%20Res%20Commun%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B400%26lt%3B%5C%2Fi%26gt%3B%2C%20619%26%23x2013%3B624.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bbrc.2010.08.114%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bbrc.2010.08.114%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Potent%20in%20vivo%20suppression%20of%20inflammation%20by%20selectively%20targeting%20the%20high%20affinity%20conformation%20of%20integrin%20%5Cu03b14%5Cu03b21%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Vanderslice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darren%20G.%22%2C%22lastName%22%3A%22Woodside%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20R.%22%2C%22lastName%22%3A%22Caivano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Radford%22%2C%22lastName%22%3A%22Decker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christy%20L.%22%2C%22lastName%22%3A%22Munsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sidney%20J.%22%2C%22lastName%22%3A%22Sherwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wanda%20S.%22%2C%22lastName%22%3A%22Lejeune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuko%20J.%22%2C%22lastName%22%3A%22Miyamoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20W.%22%2C%22lastName%22%3A%22McIntyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20G.%22%2C%22lastName%22%3A%22Tilton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%20F.%22%2C%22lastName%22%3A%22Dixon%22%7D%5D%2C%22abstractNote%22%3A%22The%20development%20of%20antagonists%20to%20the%20%5Cu03b14%20integrin%20family%20of%20cell%20adhesion%20molecules%20has%20been%20an%20active%20area%20of%20pharmaceutical%20research%20to%20treat%20inflammatory%20and%20autoimmune%20diseases.%20Presently%20being%20tested%20in%20human%20clinical%20trials%20are%20compounds%20selective%20for%20%5Cu03b14%5Cu03b21%20%28VLA-4%29%20as%20well%20as%20several%20dual%20antagonists%20that%20inhibit%20both%20%5Cu03b14%5Cu03b21%20and%20%5Cu03b14%5Cu03b27.%20The%20value%20of%20a%20dual%20versus%20a%20selective%20small%20molecule%20antagonist%20as%20well%20as%20the%20consequences%20of%20inhibiting%20different%20affinity%20states%20of%20the%20%5Cu03b14%20integrins%20have%20been%20debated%20in%20the%20literature.%20Here%2C%20we%20characterize%20TBC3486%2C%20a%20N%2CN-disubstituted%20amide%2C%20which%20represents%20a%20unique%20structural%20class%20of%20non-peptidic%2C%20small%20molecule%20VLA-4%20antagonists.%20Using%20a%20variety%20of%20adhesion%20assay%20formats%20as%20well%20as%20flow%20cytometry%20experiments%20using%20mAbs%20specific%20for%20certain%20activation-dependent%20integrin%20epitopes%20we%20demonstrate%20that%20TBC3486%20preferentially%20targets%20the%20high%20affinity%20conformation%20of%20%5Cu03b14%5Cu03b21%20and%20behaves%20as%20a%20ligand%20mimetic.%20The%20antagonist%20is%20capable%20of%20blocking%20integrin-dependent%20T-cell%20co-activation%20in%20vitro%20as%20well%20as%20proves%20to%20be%20efficacious%20in%20vivo%20at%20low%20doses%20in%20two%20animal%20models%20of%20allergic%20inflammation.%20These%20data%20suggest%20that%20a%20small%20molecule%20%5Cu03b14%20integrin%20antagonist%20selective%20for%20%5Cu03b14%5Cu03b21%20over%20%5Cu03b14%5Cu03b27%20and%2C%20specifically%2C%20selective%20for%20the%20high%20affinity%20conformation%20of%20%5Cu03b14%5Cu03b21%20may%20prove%20to%20be%20an%20effective%20therapy%20for%20multiple%20inflammatory%20diseases%20in%20humans.%22%2C%22date%22%3A%22Oct%2001%2C%202010%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bbrc.2010.08.114%22%2C%22ISSN%22%3A%221090-2104%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WGZKEVDQ%22%2C%22BBMMGS3D%22%2C%227XFQVVGN%22%2C%224R4R39JD%22%2C%225JE7K4DG%22%5D%2C%22dateModified%22%3A%222018-05-02T21%3A09%3A58Z%22%7D%7D%5D%7D

Hickman, A., Koetsier, J., Kurtanich, T. et al. (2022). LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest 132, e154152. https://doi.org/10.1172/JCI154152.

Bakthavatsalam, D., Craft, J. W., Kazansky, A. et al. (2020). Identification of Inhibitors of Integrin Cytoplasmic Domain Interactions With Syk. Front Immunol 11, 575085. https://doi.org/10.3389/fimmu.2020.575085.

Woodside, D. G., Tanifum, E. A., Ghaghada, K. B. et al. (2018). Magnetic resonance imaging of atherosclerotic plaque at clinically relevant field strengths (1T) by targeting the integrin α4β1. Sci Rep 8, 3733. https://doi.org/10.1038/s41598-018-21893-x.

Vanderslice, P., Biediger, R. J., Woodside, D. G. et al. (2013). Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion. J Biol Chem 288, 19414–19428. https://doi.org/10.1074/jbc.M113.479634.

Haidari, M., Zhang, W., Caivano, A. et al. (2012). Integrin α2β1 mediates tyrosine phosphorylation of vascular endothelial cadherin induced by invasive breast cancer cells. J Biol Chem 287, 32981–32992. https://doi.org/10.1074/jbc.M112.395905.

Gundlach, C. W., Caivano, A., Cabreira-Hansen, M. da G. et al. (2011). Synthesis and evaluation of an anti-MLC1 × anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium. Bioconjug Chem 22, 1706–1714. https://doi.org/10.1021/bc200309h.

Vanderslice, P., Woodside, D. G., Caivano, A. R. et al. (2010). Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1. Biochem Biophys Res Commun 400, 619–624. https://doi.org/10.1016/j.bbrc.2010.08.114.

Texas Heart Institute Positions

Interests

Education

Undergraduate:

Publications

Recent News

The Texas Heart Institute Shines at the BioHouston Chili Cook-off

A Beautiful Painting by THI Artist and Scientist Unveiled

The Texas Heart Institute Energizes BioHouston’s Chili Cook-Off